UNSPSC 51461522: Eyebright

This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C9642I91WL, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 502558 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Lamiales, Family Orobanchaceae, Genus Euphrasia L. (eyebright), Species Euphrasia stricta, commonly known as DRUG EYEBRIGHT, EYEBRIGHT, or as here, EUPHRASIA.

Euphrasia bears the USDA PLANTS Database Identifier EUST7. European Medicines Agency schedules euphrasia in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB45067 and SUB13783MIG. SMILES: NONE.

UNSPSC 51461522 Eyebright, a Commodity code, encompasses pharmaceutical and over-the-counter (OTC) products that state and local governments procure through cooperative purchasing arrangements. State and local health departments, correctional facilities, public hospitals, and other government health agencies source individual pharmaceutical products and OTC remedies through multi-state cooperative agreements rather than through direct individual solicitations. Issuing bodies include state agencies administering health and human services, state procurement offices managing cooperative purchasing vehicles, and participating local government health facilities. Recent activity centers on multistate cooperative purchasing alliances establishing framework agreements with pharmaceutical manufacturers and distributors to supply identified products at negotiated pricing across multiple jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities, including Oregon. MMCAP required vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and to certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA). Evaluation weighted price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, administrative fee compliance, EDI capability, and agreement to a 3 percent administrative fee. The contract term runs two years for new responders with optional extensions at MMCAP's discretion, with awarded agreements effective July 1, 2026. No specific set-aside or disadvantaged-enterprise restrictions were identified in the solicitation.